The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Coleman CN, Colby TV, Cox RS, Rosenberg SA. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann. Intern. Med.104(6), 747–756 (1986).
   PubMed Web of Science ®Google Scholar
• Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC. Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br. J. Cancer69(6), 1088–1093 (1994).
   PubMed Web of Science ®Google Scholar
• Hallahan DE, Farah R, Vokes EE et al. The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone. Int. J. Radiat. Oncol. Biol. Phys.17(4), 767–771 (1989).
   PubMed Web of Science ®Google Scholar
• Landberg TG, Hakansson LG, Moller TR et al. CVP-remission-maintenance in stage I or II non-Hodgkin’s lymphomas: preliminary results of a randomized study. Cancer44(3), 831–838 (1979).
   PubMed Web of Science ®Google Scholar
• Monfardini S, Banfi A, Bonadonna G et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I–II non-Hodgkin’s lymphoma. Int. J. Radiat. Oncol. Biol. Phys.6(2), 125–134 (1980).
   PubMed Web of Science ®Google Scholar
• Nissen NI, Ersboll J, Hansen HS et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I–II non-Hodgkin’s lymphomas. Cancer52(1), 1–7 (1983).
   PubMed Web of Science ®Google Scholar
• Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer71(7), 2342–2350 (1993).
   PubMed Web of Science ®Google Scholar
• Carde P, Burgers JM, van Glabbeke M et al. Combined radiotherapy–chemotherapy for early stages non-Hodgkin’s lymphoma: the 1975–1980 EORTC controlled lymphoma trial. Radiother. Oncol.2(4), 301–312 (1984).
   PubMed Web of Science ®Google Scholar
• Longo DL, Glatstein E, Duffey PL et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J. Clin. Oncol.7(9), 1295–1302 (1989).
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Voss N, Fairey R et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J. Clin. Oncol.20(1), 197–204 (2002).
   PubMed Web of Science ®Google Scholar
• Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann. Intern. Med.107(1), 25–30 (1987).
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol.23(18), 4117–4126 (2005).
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA et al. Rituximab–CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol.24(19), 3121–3127 (2006).
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. J. Clin. Oncol.7(5), 379–391 (2006).
   Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). J. Clin. Oncol.9(2), 105–116 (2008).
   Google Scholar
• Recher C CB, Haioun C et al. A prospective, randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs. standard R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL). Groupe d’Etude Des Lymphomes De l’Adulte (GELA) study LNH03–2B. Blood (52nd ASH Annual Meeting), Abstract 109 (2010).
   Google Scholar
• Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann. Oncol.13(Suppl. 1), 79–83 (2002).
   PubMed Web of Science ®Google Scholar
• Lee CK. Evolving role of radiation therapy for hematologic malignancies. Hematol. Oncol. Clin. North Am.20(2), 471–503 (2006).
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med.339(1), 21–26 (1998).
   PubMed Web of Science ®Google Scholar
• Horning SJ, Weller E, Kim K et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J. Clin. Oncol.22(15), 3032–3038 (2004).
   PubMed Web of Science ®Google Scholar
• Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol.25(7), 787–792 (2007).
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N. Engl. J. Med.352(12), 1197–1205 (2005).
   PubMed Web of Science ®Google Scholar
• Ballonoff A, Rusthoven KE, Schwer A et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int. J. Radiat. Oncol. Biol. Phys.72(5), 1465–1471 (2008).
   PubMed Web of Science ®Google Scholar
• Phan J, Mazloom A, Jeffrey Medeiros L et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J. Clin. Oncol.28(27), 4170–4176 (2010).
   PubMedGoogle Scholar
• Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N. Engl. J. Med.356(23), 2399–2405 (2007).
   PubMed Web of Science ®Google Scholar
• Powell ME. Modern radiotherapy and cervical cancer. Int J Gynecol Cancer20(11 Suppl. 2), S49–S51 (2010).
   PubMed Web of Science ®Google Scholar
• Alvarez Secord A, Havrilesky LJ, Bae-Jump V et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol. Oncol.107(2), 285–291 (2007).
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Cetina L, Mariscal I, de la Garza J. Modern management of locally advanced cervical carcinoma. Cancer Treat. Rev.29(5), 389–399 (2003).
   PubMed Web of Science ®Google Scholar
• Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. Semin. Radiat. Oncol.20(1), 58–66 (2010).
   PubMed Web of Science ®Google Scholar
• Wolden SL, Alektiar KM. Sarcomas across the age spectrum. Semin. Radiat. Oncol.20(1), 45–51 (2010).
   PubMed Web of Science ®Google Scholar
• Yahalom J. Does radiotherapy still have a place in Hodgkin lymphoma? Curr. Hematol. Malig. Rep.4(3), 117–124 (2009).
   PubMedGoogle Scholar
• Straus DJ. The case for chemotherapy only for localized Hodgkin lymphoma. Oncologist14(12), 1225–1231 (2009).
   PubMed Web of Science ®Google Scholar
• Klimm B, Engert A. Combined modality treatment of Hodgkin’s lymphoma. Cancer J.15(2), 143–149 (2009).
   PubMed Web of Science ®Google Scholar
• Herbst C, Engert A. Meta-analyses of early-stage hodgkin lymphoma. Acta Haematol125(1–2), 32–38 (2011).
   PubMed Web of Science ®Google Scholar
• Eich HT, Diehl V, Gorgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J. Clin. Oncol.28(27), 4199–4206 (2010).
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N. Engl. J. Med.363(7), 640–652 (2010).
   PubMed Web of Science ®Google Scholar
• Herbst C, Rehan FA, Brillant C et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica95(3), 494–500 (2010).
   PubMed Web of Science ®Google Scholar
• Engert A, Eichenauer DA, Dreyling M. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v168–v171 (2010).
   PubMed Web of Science ®Google Scholar
• Miller TP, LeBlanc M, Spier CM. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphoma: update of the Southwest Oncology Groups (SWOG) randomized trial. Blood98(98), 724a (2001).
   Google Scholar
• No authors listed. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N. Engl. J. Med.329(14), 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.26(19), 3159–3165 (2008).
   PubMed Web of Science ®Google Scholar
• Moser EC, Noordijk EM, van Leeuwen FE et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood107(7), 2912–2919 (2006).
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Ballonoff A, Rusthoven KE et al. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis. Int. J. Radiat. Oncol. Biol. Phys.76(3), 845–849 (2010).
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer10, 337 (2010).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep.62(6), 873–879 (1978).
   PubMedGoogle Scholar
• Carver JR, Shapiro CL, Ng A et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol.25(25), 3991–4008 (2007).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med.91(5), 710–717 (1979).
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood102(13), 4284–4289 (2003).
   PubMed Web of Science ®Google Scholar
• Tilly H, Mounier N, Lederlin P et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87–1 study. Groupe d’Etudes des Lymphomes de l’Adulte. J. Clin. Oncol.18(6), 1309–1315 (2000).
   PubMed Web of Science ®Google Scholar
• Andre M, Mounier N, Leleu X et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood103(4), 1222–1228 (2004).
   PubMed Web of Science ®Google Scholar
• Fillet G, Bonnet C. In Reply. J. Clin. Oncol.25(19), 2857–2858 (2007).
   PubMedGoogle Scholar
• Tsoutsou PG, Belkacemi Y, Gligorov J et al. Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. Oncologist15(11), 1169–1178 (2010).
   PubMed Web of Science ®Google Scholar
• Wyatt RM, Jones BJ, Dale RG. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br. J. Radiol.81(967), 549–563 (2008).
   PubMed Web of Science ®Google Scholar
• Persky DO, Unger JM, Spier CM et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J. Clin. Oncol.26(14), 2258–2263 (2008).
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Illidge T, Huglo D et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood110(1), 54–58 (2007).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Rossi G, Franceschetti S et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin. Cancer Res.16(15), 3998–4004 (2010).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S et al. A Phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann. Oncol.19(4), 769–773 (2008).
   PubMed Web of Science ®Google Scholar
• Miller TP, Unger JM, Spier CM. Effect of adding ibritumomab tiuxetan (zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313). Blood112(11), (2008) (Abstract 3598).
   Google Scholar
• Swerdlow AJ, Schoemaker MJ, Allerton R et al. Lung cancer after Hodgkin’s disease: a nested case–control study of the relation to treatment. J. Clin. Oncol.19(6), 1610–1618 (2001).
   PubMed Web of Science ®Google Scholar
• Hill DA, Gilbert E, Dores GM et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood106(10), 3358–3365 (2005).
   PubMed Web of Science ®Google Scholar
• Travis LB, Hill DA, Dores GM et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA290(4), 465–475 (2003).
   PubMed Web of Science ®Google Scholar
• Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J. Natl Cancer Inst.94(3), 182–192 (2002).
   PubMed Web of Science ®Google Scholar
• Brennan P, Scelo G, Hemminki K et al. Second primary cancers among 109 000 cases of non-Hodgkin’s lymphoma. Br. J. Cancer93(1), 159–166 (2005).
   PubMed Web of Science ®Google Scholar
• Lavey RS, Eby NL, Prosnitz LR. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer66(1), 80–88 (1990).
   PubMed Web of Science ®Google Scholar
• Mudie NY, Swerdlow AJ, Higgins CD et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J. Clin. Oncol.24(10), 1568–1574 (2006).
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin’s lymphoma: a GISL cohort study. Haematologica93(9), 1335–1342 (2008).
   PubMed Web of Science ®Google Scholar
• Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis. Ann. Oncol.22(8), 1845–1858 (2011).
   PubMed Web of Science ®Google Scholar
• Morton LM, Curtis RE, Linet MS et al. Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J. Clin. Oncol.28(33), 4935–4944 (2010).
   PubMed Web of Science ®Google Scholar
• Moser EC, Noordijk EM, van Leeuwen FE et al. Risk of second cancer after treatment of aggressive non-Hodgkin’s lymphoma; an EORTC cohort study. Haematologica91(11), 1481–1488 (2006).
   PubMed Web of Science ®Google Scholar
• Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin’s disease. N. Engl. J. Med.322(1), 7–13 (1990).
   PubMed Web of Science ®Google Scholar
• Kaldor JM, Day NE, Pettersson F et al. Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med.322(1), 1–6 (1990).
   PubMed Web of Science ®Google Scholar
• Haas JF, Kittelmann B, Mehnert WH et al. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br. J. Cancer55(2), 213–218 (1987).
   PubMed Web of Science ®Google Scholar
• Gomez GA, Aggarwal KK, Han T. Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin’s lymphoma. Cancer50(11), 2285–2288 (1982).
   PubMed Web of Science ®Google Scholar
• Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J. Clin. Oncol.21(5), 897–906 (2003).
   PubMed Web of Science ®Google Scholar
• Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer107(1), 108–115 (2006).
   PubMed Web of Science ®Google Scholar
• Travis LB, Weeks J, Curtis RE et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin’s lymphoma. J. Clin. Oncol.14(2), 565–571 (1996).
   PubMed Web of Science ®Google Scholar
• Friedman DL, Kadan-Lottick NS, Whitton J et al. Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev.14(8), 1922–1927 (2005).
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Falk S et al. Radiation dose in non-Hodgkin’s lymphoma: preliminary results of a UK NCRN randomised trial. Ann. Oncol. (2005).
   Google Scholar
• Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature403(6769), 503–511 (2000).
   PubMed Web of Science ®Google Scholar
• Ninan MJ, Wadhwa PD, Gupta P. Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leuk. Lymphoma52(3), 360–373 (2011).
   PubMed Web of Science ®Google Scholar
• Sehn SK, Hoskins P et al. Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. Ann. Oncol.19(Suppl. 4), Abstract 052 (2008).
   Google Scholar